Our Insights

I2U has created several case studies to identity and illuminate the discrete challenges preventing the value maximization of breakthrough medicines, and lessons learned for future innovations. To uncover these challenges, I2U conducted interviews with a wide range of system leaders and stakeholders, supported by extensive background research on implementation challenges and approaches across Canada and in a focused group of comparator jurisdictions.

CAR-T THERAPIES

A Retrospective Case Study on a Novel Immunotherapy

 

Read More

LUXTURNA

A Retrospective Case Study on a Specialized Gene Therapy

 

Read More

LEQEMBI

A Prospective Case Study on a New Alzheimer’s Drug

Read More

CRISPR

A snapshot case study on CRISPR/Cas9 Technology for Blood Disorders

 

Read More

Looking across these case studies, I2U identified 7 distinct implementation challenges each with the potential to diminish the optimal patient and system impact of a given breakthrough medicine:

Recent Webinars

January 17, 2025

Helping Health Systems Better Prepare for Breakthrough Medicines: Profiling an Innovative New Tool

https://www.youtube.com/watch?v=kAy_08AXbVg

June 1, 2023

Maximizing the Uptake of Breakthrough Medicines Across Canada: Lessons from CAR-T
https://www.youtube.com/watch?v=qd_64OqEOpI